Phase I Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors

Neil Senzer1-3, John Nemunaitis1-3, Derek Nemunaitis1, Cynthia Bedell1, Gerald Edelman1,2, Minal Barve1,2, Robert Nunan1, Kathleen F Pirollo4, Antonina Rait4 and Esther H Chang4,5

1Mary Crowley Cancer Research Centers, Dallas, Texas, USA; 2Texas Oncology, P.A., Dallas, Texas, USA; 3Medical City Dallas Hospital, Dallas, Texas, USA; 4Georgetown University Medical Center, Washington, DC, USA; 5SynerGene Therapeutics, Inc., Potomac, Maryland, USA

SELECTIVE DELIVERY OF THERAPEUTIC MOLECULES TO PRIMARY AND METASTATIC TUMORS IS OPTIMAL FOR EFFECTIVE CANCER THERAPY. A LIPOSOMAL NANODELIVERY COMPLEX (scL) FOR SYSTEMIC, TUMOR-TARGETING DELIVERY OF ANTICANCER THERAPEUTICS HAS BEEN DEVELOPED. scL EMPLOYS AN ANTI-TRANSFERRIN RECEPTOR (TfR), scFv AS THE TARGETING MOLECULE. LOSS OF p53 SUPPRESSOR FUNCTION, THROUGH MUTATIONS OR INACTIVATION OF THE p53 PATHWAY, IS PRESENT IN MOST HUMAN CANCERS. RATHER THAN BEING TRANSIENTLY PERMISSIVE FOR TUMOR INITIATION, PERISTENCE OF p53 DYSFUNCTION IS A CONTINUING REQUIREMENT FOR MAINTAINING TUMOR GROWTH. HEREIN, WE REPORT RESULTS OF A FIRST-IN-MAN PHASE I CLINICAL TRIAL OF RESTORATION OF THE NORMAL HUMAN TUMOR SUPPRESSOR GENE p53 USING THE scL NANO-COMPLEX (SGT-53). MINIMAL SIDE EFFECTS WERE OBSERVED IN THIS TRIAL IN PATIENTS WITH ADVANCED SOLID TUMORS. FURTHERMORE, THE MAJORITY OF PATIENTS DEMONSTRATED STABLE DISEASE. ONE PATIENT WITH ADENOID CYSTIC CARCINOMA HAD HIS STATUS CHANGED FROM UNRESECTABLE TO RESECTABLE AFTER ONE TREATMENT CYCLE. MORE SIGNIFICANTLY, WE OBSERVED AN ACCUMULATION OF THE TRANSGENE IN METASTATIC TUMORS, BUT NOT IN NORMAL SKIN TISSUE, IN A DOSE-RELATED MANNER. THESE RESULTS SHOW NOT ONLY THAT SYSTEMICALLY DELIVERED SGT-53 IS WELL TOLERATED AND EXHIBITS ANTICANCER ACTIVITY, BUT ALSO SUPPLY EVIDENCE OF TARGETED TUMOR DELIVERY OF SGT-53 TO METASTATIC LESIONS.

INTRODUCTION

The p53 “suppressor gene” is the most frequently annotated gene mutation in human cancer.1,2 Loss of p53 suppressor function, either through mutations or inactivation of the p53 pathway, is present in most if not all human cancers.2-4 Both p53 mutation and pathway dysfunction are associated with poor clinical outcomes,5-12 and the presence of the mutation correlates with resistance to chemotherapy and radiation.13 The p53 gene encodes a transcription factor with >540 binding loci thus far identified,14 and plays a dominant role in the induction of cell cycle arrest, DNA repair, apoptosis, and senescence as well as in mediating bystander antitumor effects.6,15,16 In addition, p53 appears to play a role in stem cell, including cancer stem cell, homeostasis in part by regulating the polarity of self-renewing divisions.17,18 Although loss of p53 functionality is known to result in increased genetic instability, impaired growth arrest, and inappropriate cell survival, it was only recently shown that, rather than being merely transiently permissive for tumor initiation, persistence of p53 dysfunction is a continuing requirement for maintaining tumor growth.19-21

Several gene therapy clinical trials using adenoviral delivery aimed at restoring functional p53 have been initiated or conducted by us and others,22-26 in which intratumoral administration resulted in both complete local positron emission tomography/computed tomography imaging response,27 and biopsy documented pathological complete responses (in conjunction with radiation therapy).28 Despite these impressive local responses, the widespread clinical application of this documented effective therapeutic gene approach restoring a driver suppressor oncogene has been delayed due to the inability of such intratumoral approaches to treat metastatic disease, as well as to the lack of a systemic delivery vehicle to effectively deliver the gene therapy to both the primary and metastatic sites.

SGT-53 is a therapeutic complex comprised of a cationic liposome encapsulating a plasmid encoding normal human wild-type (wt) p53 DNA. The liposome is decorated with an anti-transferrin receptor (TfR) single-chain antibody fragment (scFv) designed to target cancer cells via the transferrin glycoprotein receptor, which is ubiquitous, highly expressed on tumor cells, and efficiently internalized.29-31 This complex has been shown to effectively and specifically deliver the p53 cDNA to tumor cells, both primary and metastatic, via receptor-mediated endocytosis of the cationic liposomal complex.32-38 More significantly, preclinical studies of the systemic (intravenous) delivery of the SGT-53 nanocomplex have also demonstrated significant antitumor activity, resulting in tumor growth inhibition and long-term regression in a variety of solid tumor preclinical models, when used in combination with chemotherapy and radiation.32,33 Based on the selective tumor-targeting ability and the therapeutic potential shown by the platform technology described above, the prototype of this technology, SGT-53, was advanced into human clinical trials.

Thus, the current Phase I study of systemically delivered SGT-53 in advanced cancer patients was designed to assess safety, to confirm the presence of the transgene in the tumors, and to...
determine whether there is a dose-dependent level of the transgene in the tumors. Demonstrating that the systemically administered exogenous wt p53 delivered via SGT-53 was indeed present in the tumors would be a significant advance in the field of systemic gene therapy, as this is a result which has been difficult to achieve with other approaches. Human tumors in patients are notoriously difficult to transfect.39 Despite the large number of clinical trials, with the exception of one report by Davis et al.,40 there is very little

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Type of cancer (histology)</th>
<th>Stage of disease at entry</th>
<th>Previous XRT (number of cycles)</th>
<th>Previous chemo Tx (number of regiments)</th>
<th>Previous biological Tx</th>
<th>Age</th>
<th>Sex</th>
<th>Target sites of disease</th>
<th>Non-target sites of disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>02-003</td>
<td>Thyroid (medullary)</td>
<td>4</td>
<td>4</td>
<td>0</td>
<td>2</td>
<td>64</td>
<td>Male</td>
<td>Right lower neck mass, right anterior hepatic lobe metastasis, left para-aortic node, right iliac bone lesion</td>
<td>Multiple sub-centimeter pulmonary nodules, multiple sub-centimeter liver lesions, multiple sub-centimeter bone lesions</td>
</tr>
<tr>
<td>02-006</td>
<td>Colon (adenocarcinoma)</td>
<td>4</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>75</td>
<td>Female</td>
<td>Right upper lobe lung nodule, left upper lobe lung nodule, left lower lobe lung nodule, right hepatic lesion</td>
<td>Left hilar adenopathy</td>
</tr>
<tr>
<td>02-007</td>
<td>Head and neck (adenoid cystic carcinoma)</td>
<td>4</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>47</td>
<td>Male</td>
<td>Right maxillary mass</td>
<td>None</td>
</tr>
<tr>
<td>02-008</td>
<td>Thymoma (epithelial)</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>2</td>
<td>46</td>
<td>Male</td>
<td>Right upper lobe nodule, right upper lobe nodule (2), left lower lobe nodule, T9 sclerotic lesion, Calcified mass anterior mediastinum</td>
<td>T8 sclerotic lesion-rib</td>
</tr>
<tr>
<td>02-010</td>
<td>Rectum (squamous cell carcinoma)</td>
<td>4</td>
<td>1</td>
<td>4</td>
<td>0</td>
<td>70</td>
<td>Male</td>
<td>RUL nodule, LLL superior segment, RML nodule, right lobe liver, medial segment left lobe, lateral segment left lobe, left adrenal mass</td>
<td>None</td>
</tr>
<tr>
<td>02-011</td>
<td>Colon (adenocarcinoma)</td>
<td>4</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>46</td>
<td>Female</td>
<td>Left suprarenal mass, anterior to left kidney, left posterolateral wall, left posterior wall</td>
<td>Left psoas met</td>
</tr>
<tr>
<td>02-012</td>
<td>Vaginal (adenocarcinoma)</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>55</td>
<td>Female</td>
<td>Lesion adjacent to left common iliac artery</td>
<td>Left hydronephrosis</td>
</tr>
<tr>
<td>02-013</td>
<td>Nasopharyngeal (poorly differentiated carcinoma)</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>38</td>
<td>Male</td>
<td>Left infrachilar mass</td>
<td>Left pleural effusion, pericardial effusion, nonspecific RUL nodule, nonspecific asymmetric enlargement of left tonsil</td>
</tr>
<tr>
<td>02-014</td>
<td>Cervical (squamous cell carcinoma)</td>
<td>4</td>
<td>1</td>
<td>6</td>
<td>0</td>
<td>57</td>
<td>Female</td>
<td>Omental met in hernia, Supraumbilical omental met, right pericaeal met, left pericaeal met</td>
<td>Nonspecific sigmoid colon wall thickening, ventral hernia omental mets</td>
</tr>
<tr>
<td>02-015</td>
<td>Vaginal (invasive squamous cell carcinoma)</td>
<td>4</td>
<td>2</td>
<td>6</td>
<td>0</td>
<td>68</td>
<td>Female</td>
<td>RUL lung, RUL lung (2), posterior right lobe liver, medial left lobe liver</td>
<td>Lung mets, liver mets</td>
</tr>
<tr>
<td>02-016</td>
<td>Colorectal (adenocarcinoma)</td>
<td>4</td>
<td>0</td>
<td>5</td>
<td>2</td>
<td>37</td>
<td>Male</td>
<td>RLL lung, RLL lung (2), left lobe liver, right lobe liver, right lobe liver (2), abdominal node, right iliac fossa node</td>
<td>Lung nodules, liver nodules, mesenteric nodes</td>
</tr>
</tbody>
</table>

Abbreviations: LLL, left lower lobe; met, metastasis; RLL, right lower lobe; RUL, right upper lobe; Tx, treatment; XRT, radiation. *Three local XRT, one systemic therapy with I131.*
evidence that the systemically delivered gene therapy payload is actually present in the target tumors.

RESULTS

Patient population

Eleven previously treated patients with refractory cancer (Table 1) and no available standard of care options received 99 infusions of SGT p53 over four sequential dosing cohorts; 0.6, 1.2, 2.4, and 3.6 mg DNA per infusion (Table 2).

Safety

One patient (patient ID 02-007; 0.6 mg DNA per infusion) developed a possibly related grade 3 (fatigue) adverse event. During the course of treatment with SGT-53, this patient, who had head and neck cancer (adenoid cystic carcinoma), experienced severe necrosis of his tumor and underwent debridement of the tumor. The one time grade 3 level of fatigue coincided temporally with this event. Similar to what we observed preclinically in mice, we hypothesize that this massive level of cell death might have been contributory to the fatigue observed.

Two serious adverse events, chest pain and tachycardia were observed in the same patient (patient ID 02-015; 3.6 mg DNA per infusion). These were classified as grade 2 and only possibly related to the study drug. Drug-related grade 1, 2 adverse events occurring in ≥5% of patients are shown in Table 3. These primarily consisted of transient fever starting 6–8 hours after infusion and lasting 12–16 hours (5 of 11; 46%) and transient hypotension over a similar time frame in 7 (7 of 11; 64%). These low-grade toxicities justified our prophylactic regimen involving hydration, tylenol, histamine blockade, and indocin as described in Materials and Methods. No maximum tolerated dose was defined. Insofar, as significant exogenous p53 wt levels by PCR were detected in two tumor samples at the 3.6 mg DNA dose level (Figure 1), further dose escalation was discontinued.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Number of infusions</th>
<th>Dose/injection</th>
</tr>
</thead>
<tbody>
<tr>
<td>02-003 a</td>
<td>1</td>
<td>0.6 mg</td>
</tr>
<tr>
<td>02-006</td>
<td>10</td>
<td>0.6 mg</td>
</tr>
<tr>
<td>02-007 b</td>
<td>20</td>
<td>0.6 mg</td>
</tr>
<tr>
<td>02-008</td>
<td>10</td>
<td>1.2 mg</td>
</tr>
<tr>
<td>02-010</td>
<td>10</td>
<td>2.4 mg</td>
</tr>
<tr>
<td>02-011 c</td>
<td>8</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>02-012</td>
<td>10</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>02-013</td>
<td>10</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>02-014</td>
<td>10</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>02-015 d</td>
<td>6</td>
<td>3.6 mg</td>
</tr>
<tr>
<td>02-016 e</td>
<td>4</td>
<td>3.6 mg</td>
</tr>
</tbody>
</table>

Abbreviations: SAE, serious adverse event; SD, stable disease. aEarly termination due to an SAE (right coronary artery occlusion) unrelated to the study drug. bThis patient received two cycles (10 infusions each) of study drug as a result of SD. cTwo infusions (numbers, three and seven) not done due to elevated liver enzymes and anemia, respectively. dEarly termination due to disease progression. eEarly termination due to clinical progression.

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Possible adverse events</th>
<th>Relation to study drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>02-003</td>
<td>None</td>
<td>Intermittent diarrhea, intermittent dehydration, hypotension</td>
</tr>
<tr>
<td>02-006</td>
<td>None</td>
<td>Fever, hypotension, headache, tachycardia, chills</td>
</tr>
<tr>
<td>02-007</td>
<td>Fever, neutropenia, fatigue, dehydration, phlebitis IV site (L), chill</td>
<td>Fever, tumor necrosis in mouth</td>
</tr>
<tr>
<td>02-008</td>
<td>Cramps on right toes, body aches</td>
<td>Hypotension</td>
</tr>
<tr>
<td>02-010</td>
<td>Diarrhea</td>
<td>None</td>
</tr>
<tr>
<td>02-011</td>
<td>Dizziness, headache, oral ulcer, light headed, tachycardia, fatigue, anorexia, anemia, elevated D-dimer</td>
<td>Leukopenia, elevated AST, elevated ALT, hypotension, neutropenia, fever</td>
</tr>
<tr>
<td>02-012</td>
<td>Elevated LDH, anemia, fatigue</td>
<td>Hypotension</td>
</tr>
<tr>
<td>02-013</td>
<td>Mild nausea, anorexia</td>
<td>Stomatitis, anemia</td>
</tr>
<tr>
<td>02-014</td>
<td>Diarrhea, intermittent diarrhea</td>
<td>None</td>
</tr>
<tr>
<td>02-015</td>
<td>Diffuse patchy infiltrates, wheezing, flushed, fluid overload, intermittent nausea, transient SOB, tachycardia, dyspepsia, neutropenia, hypomagnesemia</td>
<td>Fatigue</td>
</tr>
<tr>
<td>02-016</td>
<td>Diarrhea, fatigue, weakness, mild nausea, blurred vision, flushing, depression, dizziness, malaise, insomnia, light headedness, chest tightness, dyspnea on exertion, nervousness, choking feeling, headache, weight loss, increased shortness of breath, nausea</td>
<td>None</td>
</tr>
</tbody>
</table>

Abbreviations: AE, adverse event; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase; SOB, shortness of breath.
Response

Despite the limitations of a Phase I study vis-à-vis assessment of response, 7 of the 11 patients demonstrated stable disease at week 6 assessment, one was unevaluable and three had progressive disease (Table 4). Median survival was 340 days (Table 4). Moreover, the tumor in patient 02-007 underwent significant necrosis and was reclassified from inoperable to operable. In a second patient (02-010), computed tomography assessment post-treatment showed that the liver metastases all had developed necrotic centers.

Tumor biopsies for assessment of the presence of exogenous p53 were obtained from metastatic lesions in three patients. One patient, 02-007, with adenoid cystic carcinoma sampled at 100 hours post-injection, had received the 0.6 mg dose level, which was the lowest dose administered. Patients 02-011 (adenocarcinoma of the colon), sampled at 26 hours, and 02-014 (squamous cell carcinoma of cervix), sampled at 73 hours, both were treated at the 3.6 mg DNA dose, the highest dose infused. Results from the DNA PCR analysis for the presence of exogenous p53 DNA in the tumors are shown in Figure 1a with positive (pSCMV-p53 plasmid DNA) and negative (normal skin biopsy) controls (patient 02-14, normal tissue sampled at 71 hours). Reverse transcription PCR to determine transgene expression was not applicable for these studies because it would not be able to unequivocally establish that the p53 protein detected was from the exogenous transgene. In contrast, since we could design primers that included part of the plasmid vector backbone, only the exogenous DNA would be amplified. Thus, this DNA PCR approach was used for these studies. These experiments show the clear presence of the exogenous p53 transgene in the metastatic tumor tissue from these three patients, but not in the normal skin sample, suggesting preliminary evidence of tumor localization. Moreover, a DNA dose-dependent presence of the exogenous p53 was also suggested between the tumor biopsies from the patient that received the 0.6 mg dose and those that received the 3.6 mg dose. Figure 1b is from a second experiment to confirm that exogenous p53 is present in the tumor from the patient who received the 0.6 mg dose. It is also significant that all three of the biopsies were obtained from metastatic lesions demonstrating not only the tumor-targeting ability of systemically administered SGT-53, but also its specificity for tumor over the normal skin tissue, consistent with the preclinical studies described here and elsewhere.32,33,35,41,42 Although further evaluation of intratumoral plasmid DNA stability is indicated, previous studies with Tf-lipoplexes in the preclinical studies cited above using human cells showed peak transgene expression at 48–72 hours diminishing by days 7–10.

**DISCUSSION**

This Phase I study has fulfilled its objectives demonstrating (i) the safety of systemic intravenous infusion of SGT-53 through 3.6 mg DNA per infusion, (ii) significant tumor-specific p53 transgene

---

Table 4 Response to SGT-53

<table>
<thead>
<tr>
<th>Patient ID</th>
<th>Max % increase/ decrease in the sum of longest diameter(s) (cm)</th>
<th>Max increase/ decrease in the sum of longest diameter(s) (cm)</th>
<th>Baseline sum of longest diameter(s) (cm)</th>
<th>Week 6, sum of longest diameter(s) (cm)</th>
<th>Response (6 weeks)</th>
<th>Survival (days alive from consent)</th>
<th>Reason off study</th>
</tr>
</thead>
<tbody>
<tr>
<td>02-003</td>
<td>Dec 5.3%</td>
<td>Dec 0.8</td>
<td>15.1</td>
<td>14.3</td>
<td>SD</td>
<td>392</td>
<td>Death</td>
</tr>
<tr>
<td>02-006</td>
<td>Inc 4.4%</td>
<td>Inc 0.5</td>
<td>11.3</td>
<td>11.8</td>
<td>SD</td>
<td>104</td>
<td>Death</td>
</tr>
<tr>
<td>02-007</td>
<td>Dec 1.4%</td>
<td>Dec 0.1</td>
<td>6.9</td>
<td>6.8</td>
<td>SD</td>
<td>340</td>
<td>Death</td>
</tr>
<tr>
<td>02-007a</td>
<td>Inc 6.5%</td>
<td>Inc 0.4</td>
<td>6.8</td>
<td>7.2</td>
<td>SD</td>
<td>340</td>
<td>Death</td>
</tr>
<tr>
<td>02-008</td>
<td>Dec 5.4%</td>
<td>Dec 0.5</td>
<td>9.3</td>
<td>8.8</td>
<td>SD</td>
<td>786</td>
<td>n/a</td>
</tr>
<tr>
<td>02-010</td>
<td>Inc 3.6%</td>
<td>Inc 1.6</td>
<td>45</td>
<td>46.6</td>
<td>SD</td>
<td>525</td>
<td>Death</td>
</tr>
<tr>
<td>02-011</td>
<td>Inc 34.8%</td>
<td>Inc 6.3</td>
<td>18.1</td>
<td>24.4</td>
<td>PD</td>
<td>251</td>
<td>Death</td>
</tr>
<tr>
<td>02-012</td>
<td>0</td>
<td>0</td>
<td>3.2</td>
<td>3.2</td>
<td>SD</td>
<td>454</td>
<td>n/a</td>
</tr>
<tr>
<td>02-013</td>
<td>Inc 46%</td>
<td>Inc 1.4</td>
<td>3</td>
<td>4.4</td>
<td>PD</td>
<td>447</td>
<td>n/a</td>
</tr>
<tr>
<td>02-014</td>
<td>Inc 2.8%</td>
<td>Inc 0.3</td>
<td>10.6</td>
<td>10.9</td>
<td>SD</td>
<td>220</td>
<td>Death</td>
</tr>
<tr>
<td>02-015</td>
<td>Inc 27%</td>
<td>Inc 1.7</td>
<td>6.3</td>
<td>8</td>
<td>PD</td>
<td>208</td>
<td>Death</td>
</tr>
<tr>
<td>02-016b</td>
<td>n/a</td>
<td>n/a</td>
<td>25</td>
<td>n/a</td>
<td>N/E</td>
<td>30</td>
<td>n/a</td>
</tr>
</tbody>
</table>

Abbreviations: Dec, decrease; Inc, increase; n/a, not applicable; N/E, not evaluable; PD, progressive disease; SD, stable disease.

*Cycle 2 for patient 007. “Did not finish treatment. Did not receive 6-week tumor assessment. ’Patient is still alive. Went off treatment after 30 days and has not had a follow-up visit.
presence following systemic delivery, and (iii) an apparent dose-
transgene presence relationship. Despite the proven clinical effec-
tiveness of local administration of gene therapeutics, including p53,27,28 clinically applicable systemic delivery allowing for opti-
mized blood clearance, preferential delivery to target tumor tis-
sues including metastases, target tumor cell uptake, and target tumor cell transgene presence/expression, within acceptable safety
constraints, has been elusive and continues to be an ongoing chal-
lenge.43–45 Currently, there has been only one report of systemic tar-
geted delivery of nanoparticles46 in patients with siRNA. However,
this report did not examine normal tissue for the presence of the
siRNA. Thus, this is the first report to demonstrate tumor specific-
ity as well as uptake in metastatic tumors of a systemically delivered
liposomal nanoparticle for gene therapy. The nanocomplex used
in this study is a DOTAP:DOPE cationic liposome prepared by a
previously described ethanol injection method25 decorated with an
anti-TfR single-chain antibody fragment (scFv) targeting the TfR.
A symptom-directed prophylactic regimen to attenuate generic
lipoplex-associated cytokine-mediated toxicity was devised which
allowed safe outpatient administration.

One of the most significant findings to arise from this study is
the high level of p53 transgene in the metastatic tumors that was
documented at an administered systemic dose of 3.6 mg DNA in
two patients without evidence of presence in a concurrent nor-
mal skin biopsy. Moreover, evidence of the exogenous SGT-53–
delivered p53 was present in the tumor biopsy from the patient
who received the lowest DNA dose of 0.6 mg suggesting a dose-
dependent uptake in tumors.

For an anticancer therapy to be effective it is crucial that a
significant amount of the ID accumulate in the tumor, i.e., an
amount sufficient for transgene expression in the therapeutic
range in the target organ/tissue with attenuated accumulation in
normal tissue so as to decrease potential for toxicity and focus
biodistribution. Although, we were not able to determine the per-
cent of the ID present in the tumors of the three patients from
whom tumor biopsies were obtained, the exogenous wt p53 DNA,
as evidenced by the unique PCR product, was present in the small
amounts of metastatic tumor tissues obtained by biopsy from all
three patients, even in the individual who had received the lowest
dose (0.6 mg p53 DNA) of SGT-53. All three of these patients in
this Phase I trial had a heavy tumor burden. Thus, the biopsy tis-
ue obtained represents only a miniscule portion of the complete
tumor load. The amount of DNA employed in the PCR assay is
equivalent to ~2.5 mg of tumor tissue. Based upon these results
and up to a 6.5-fold difference in tumor to normal tissue uptake
in vitro (A549 SQ xenograft),46 it is reasonable to hypothesize that
a significant percent of the ID may be taken up by the tumors
in these patients as a result of the tumor-specific nature of this
nanodelivery system.

The effectiveness of p53 restorative therapy has been demon-
strated in an elegant series of preclinical models using differing
methods of genetic manipulation.19–21 However, in all of these the
base gene status was p53−/−. At least 75% of the annotated muta-
tions in human cancer are due to missense substitutions of which
80% exert a dominant-negative effect over p53wt.47,48 In at least one
Phase III study of the intratumoral injection of a replication-de-
fective adenovirus to deliver p5345, the presence of a high-mutated
level of p53 (as indicated by nuclear staining in ≥20% of tumor cells
using a DO-7–based monoclonal antibody), was noted in the sub-
set of patients receiving single modality treatment. This mutated
p53 appeared to exhibit a dominant-negative effect inhibiting the
functionality of p53wt as evidenced by a lower rate of tumor growth
control (20 versus 71%; P = 0.0290) and shorter median survival
(2.7 versus 7.2 months; log rank P < 0.0001).24 To the contrary, in an
in vitro and in vivo evaluation of p53 restoration via a repli-
cation-deficient recombinant adenovirus in 45 human cells lines
comprised of wt, mutated, or null p53, there was no evidence that
dominant-negative mutations impaired the antiproliferative effects
of p53 wt in vitro nor did those same mutations impair the p53 wt-
mediated enhanced survival in vivo.49 A recent study of restorative
p53 for spontaneous tumors in a murine model containing the
p53R172H gain-of-function dominant-negative mutation showed
that not only did restoration produce tumor regression in p53−/−
mice, it also blocked tumor growth, albeit without regression, in
the p53R172H mice.50 It was also suggested that the response to p53
restoration was tumor type related, inducing apoptosis in lymph-
omas and senescence in angiosarcomas, similar to the findings
reported by Ventura and colleagues.21 Based on their data using
the hypomorphic p53neo allele, the authors postulated that the anti-
tumor mechanism of action of p53 is dose-dependent, i.e., high
levels of p53 expression inducing apoptosis and low levels inducing
senescence.50

Despite the prolongation of survival following p53 restoration
in the Eμ-myc lymphoma model, Martins found that the function
of the p53 pathway was eventually inactivated followed by lym-
phoma regrowth and death.51 One of the mechanisms of loss-of-
function of the p53 pathway was loss of p19ARF which negated the
p53 restoration and in these mice the therapeutic effectiveness
of p53 was restored by the addition of a p53-activating stimulus, e.g.,
radiation or chemotherapy. Likewise, Roth and associates have
previously shown that the combination of cisplatin and intratu-
moral adenoviral p53 transfection produced significant apoptotic
cell killing in the H358 non-small cell lung cancer model not seen
with either treatment alone.51

### Table 5 Dose levels for SGT-53 (based on mg of wt p53)

<table>
<thead>
<tr>
<th>Dose level</th>
<th>Dose of SGT-53 per infusion</th>
<th>Volume SGT-53</th>
<th>Volume (5% dextrose)</th>
<th>Total volume</th>
<th>Infusion time</th>
</tr>
</thead>
<tbody>
<tr>
<td>−2</td>
<td>0.2 mg per infusion</td>
<td>3.5 ml</td>
<td>46.5 ml</td>
<td>50 ml</td>
<td>0.5 hour</td>
</tr>
<tr>
<td>−1</td>
<td>0.3 mg per infusion</td>
<td>5 ml</td>
<td>45 ml</td>
<td>50 ml</td>
<td>0.5 hour</td>
</tr>
<tr>
<td>1</td>
<td>0.6 mg per infusion</td>
<td>10 ml</td>
<td>40 ml</td>
<td>50 ml</td>
<td>0.5 hour</td>
</tr>
<tr>
<td>2</td>
<td>1.2 mg per infusion</td>
<td>20 ml</td>
<td>80 ml</td>
<td>100 ml</td>
<td>1 hour</td>
</tr>
<tr>
<td>3</td>
<td>2.4 mg per infusion</td>
<td>40 ml</td>
<td>120 ml</td>
<td>160 ml</td>
<td>1.5 hours</td>
</tr>
<tr>
<td>4</td>
<td>3.6 mg per infusion</td>
<td>60 ml</td>
<td>140 ml</td>
<td>200 ml</td>
<td>2 hours</td>
</tr>
</tbody>
</table>

© The American Society of Gene & Cell Therapy
As this was a first-in-man safety study of SGT-53, it was administered as a single agent. However, its intended use is in combination with standard radio/chemotherapy treatment modalities. Preclinical studies have demonstrated that this combination treatment yields significant tumor growth inhibition and tumor regression resulting in enhanced survival. The responses observed with the single agent resulting in stable disease, whereas undergoing treatment correlate with what was observed in the preclinical studies when the tumor-targeting liposomal-p53 nano-complex was administered alone. Integrating the results of the current study with the data derived from the restoration models, a series of preclinical assessments of in vivo systemic SGT-53 and chemotherapy were devised and implemented resulting in a clinical Phase Ib study of SGT-53 combined with docetaxel, which has been activated and is accruing patients.

MATERIALS AND METHODS

Study design. This study (Trial registration ID: NCT00470613) was an open label, single center, sequential dose-escalating, Phase I study evaluating the safety, pharmacokinetics, and potential activity of SGT-53 in subjects with solid tumors and who had been offered all standard or approved therapies. We utilized an accelerated titration design for inter-participant dose escalation. Study agent administration to each subject was planned in a sequential manner, starting at 0.6 mg DNA or approved therapies. We utilized an accelerated titration design for SGT-53 in subjects with solid tumors and who had been offered all standard evaluations of SGT-53 in subjects with solid tumors and who had been offered all standard or approved therapies. We utilized an accelerated titration design for inter-participant dose escalation. Study agent administration to each subject was planned in a sequential manner, starting at 0.6 mg DNA or approved therapies. We utilized an accelerated titration design for SGT-53 in subjects with solid tumors and who had been offered all standard or approved therapies.

Study population. The intended study population included subjects with biopsy-confirmed diagnosis of solid tumors with no available standard treatment options and with biopsy accessible tumor (for assessment of transgene presence) who were registered through Mary Crowley Cancer Research Centers (MCCRC), Dallas, Texas.

Inclusion criteria. Eligible subjects met the following inclusion criteria: biopsy-confirmed diagnosis; had been offered all standard or approved therapies; had solid tumors that could be measured on physical examination or by radiographic imaging studies and were biopsy accessible; were 18 years old or older; had an ECOG (Eastern Cooperative Oncology Group) performance study of 0-2; were able to give protocol-specific informed consent; had recovered from previous therapy; female subjects of childbearing potential must have had a negative pregnancy test within 7 days before initiation of study drug (postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential); male and female subjects of reproductive potential must have agreed to use birth control measures (e.g., condoms or birth control pills) to avoid pregnancy throughout the study and for 3 months following discontinuation of the study drug; have adequate organ function characterized by ≤ grade 1 scores defined by CTCAE v3.0 and laboratory values within the following criteria: hemoglobin ≥ 10.0 gm/dl; absolute neutrophil count > 1,500/mm³; WBC count ≥ 3,000/mm³; platelet count ≥ 100,000/mm³; prothrombin time/thromboplastin time < 1.5 times the upper limit of normal; lactate dehydrogenase < 3 times the upper limit of normal; total bilirubin ≤ upper limit of normal; aspartate transaminase and alanine transaminase < 2.5 × upper limit of normal with alkaline phosphatase ≤ 2.5 × upper limit of normal; creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 50 ml/minute.

Subjects with the following characteristics were excluded: those with signs and symptoms consistent with an active infection; fever (>38.1°C); known HIV infection; fasting glucose levels > 180 mg/dl; uncontrolled diastolic blood pressure of > 90 mm Hg resting at baseline despite medication; an abnormal stress echocardiogram or unfavorable results; uncontrolled congestive heart failure; unstable angina; significant baseline neuropathies (> grade 2 based upon CTCAE v3.0); requirement for renal dialysis; requirement for systemic steroids within 30 days before study entry; receiving hematopoietic growth factors; receiving anticoagulants other than those to maintain patency of venous access lines (<2 mg warfarin); received an investigational drug within 30 days before study entry; received radiation treatment < 4 weeks before study entry; prior exposure to gene vector delivery products; or received treatment with chemotherapeutic agents < 4 weeks before study entry.

Study drug administration. Study drug was administered at MCCRC outpatient clinic twice weekly for 5 weeks for a total of 10 infusions. Infusion occurred over 1 hour for dose levels 1 and 2; over 1.5 hours for dose level 3; and over 2 hours for dose level 4. In the event of an infusion reaction, the infusion was discontinued, appropriate medication administered, and the infusion resumed at a slower infusion rate. The infusion was completed within 8 hours of dilution of study agent in dextrose. At least 3 or 4 days separated each infusion. Subjects received intravenous fluids for 2 hours after completion of each fusion.

For the first infusion of SGT-53, subjects were monitored and observed as inpatients for at least 23 hours, and up to 48 hours, from the time of admittance to MCCRC outpatient clinic. Subjects were monitored there for the first 8 hours after completion of the first infusion, during that time pharmacokinetic blood draws were taken at specified intervals. In addition, subjects received intravenous fluids for 2 hours after completion of the first infusion, with continued intravenous access for rapid fluid management if necessary. After 8 hours, subjects were then transferred and admitted to Medical City Hospital for the remainder of the observation period to monitor and manage any reactions to SGT-53. During this time, subjects continued intravenous access with maintenance of the 20-gauge catheter for rapid fluid management if necessary. At the end of the 23–48 hours observation period, subjects were discharged if medically stable.

For subsequent infusions, subjects were infused with SGT-53 in the MCCRC outpatient infusion unit. All patients received dexamethasone 8 mg intravenously for 1 hour ± 5 minutes before dosing, and a combination of histamine H1 and H2 blockers (e.g., benadryl 25 mg and pepcid 20 mg, both intravenously) 30 ± 15 minutes and indocin 25 mg, orally ~30 ± 5 minutes before receiving...
SGT-53. All patients also received acetaminophen 650 mg orally just before SGT-53 administration as prophylaxis for pyretic reactions. A final volume of 50–250 ml of SGT-53 in 5% dextrose was infused intravenously via a newly inserted venous access line or following flushing of an intact central venous line. Infusion was completed within 8 hours of dilution of study agent in dextrose. Four hours after completion of each infusion of SGT-53, subjects received acetaminophen, 650 mg orally.

**Monitoring.** Subjects had vital signs monitored every 15 ± 5 minutes during infusion and every 30 ± 5 minutes for 2 hours after each infusion. An electrocardiogram was performed on all subjects at 2 hours after each infusion.

Thereafter, the patients continued to receive intravenous fluids at ≥100 ml/hour during the 24-hour observation period. In addition, the patients continued to receive acetaminophen 650 mg orally alternating with indocin 25 mg orally every 4 hours for the first 24 hours.

**Toxicities and DLT.** Adverse events were graded according to the CTCAE v3.0 (http://ctep.cancer.gov/forms/). The following grade 2 events defined toxicities that would lead to withholding infusions of SGT-53: Grade 2 total hyperbilirubinemia, aspartate transaminase, alanine transaminase, dyspnea, and disseminated intravascular coagulation if not resolved to grade 1 or less in 2 weeks.

Otherwise, all grade 3 or grade 4 toxicities (as defined by CTCAE v3.0) within the first 5 weeks of study drug administration that had been determined by the principal investigator to be at least possibly related to study drug were considered DLT’s.

In addition, subjects who received <4 of 10 of the intended drug infusions, due to experiencing grade 2 events that had not resolved that were determined by the principal investigator to be possibly related to study drug, were considered to have experienced a DLT.

**Tumor response.** Measurable disease was defined as any lesion with clearly defined borders that could be measured with calipers on physical exam or by imaging, i.e., X-ray, computed tomography, or magnetic resonance imaging. The Response Evaluation Criteria in Solid Tumors (RECIST 1.0) criteria published in 2 February 2000, issue of JNCI (web at http://ctep.cancer.gov/protocolDevelopment/) was utilized to evaluate response.

**Levels of exogenous p53<sup>wt</sup> in tumor via DNA PCR.** In three patients, one at 0.6 mg DNA dose level and two at the 3.6 mg DNA dose levels, a biopsy of the most accessible tumor was performed within 24–96 hours after the last administration of SGT-53. At least 20 mg of tumor tissue from a safely accessible site (e.g., liver, abdomen, skin) was obtained. A microscopic examination was performed on the frozen sample to ensure that the sample contained tumor. The tumor tissue was snap frozen and was used for DNA PCR to identify the presence and level of exogenous wt p53 DNA in the tumor. In both cases, the tumor sample was obtained from a metastatic lesion.

In one patient that had received the 3.6 mg DNA dose, a skin biopsy was also performed simultaneously with the tumor biopsy. A 4 mm punch biopsy was obtained from a safely accessible site. The skin was numbed with EMLA cream and the tissue was numbed with lidocaine. The skin biopsy was performed concurrently with the tumor biopsy.

The tissues were pulverized while frozen using a Bessman Tissue Pulverizer and the DNA was isolated using the “High Pure PCR Template Preparation Kit” from Roche (Indianapolis, IN; cat. no. 1796828) and the procedures were supplied by the manufacturer. DNA concentration of each sample was determined by absorbance (260/280 nm).

**PCR design.** The presence of the exogenous p53 in the tumor and normal skin was detected using DNA PCR employing primers specific for the exogenous p53 gene. To avoid cross-contamination of sample DNA with PCR product, the preparation of the reaction and analysis of the product was performed in separate locations using dedicated reagents and equipment. Only sterile, endotoxin-free tubes, and filter tips were employed. Gloves were worn at all times and changed frequently. A new aliquot of sterile PCR grade water was used for, and disposed off, after each experiment. The pipettors were cleaned with a decontamination agent and ultraviolet-irradiated overnight.

A blank sample containing all reagents except the template was included in the experiments as a negative control. The pSCMV-p53 plasmid DNA, which is used as the payload in SGT-53, at 100 and 500 copies, was used in each set of reactions as a positive control. The amount of template DNA used in each reaction was 0.4 μg. The PCR reactions were performed using the titanium TAQ DNA PCR kit (Clontech, Mountain View, CA; cat. no. 639210). Amplification was performed on an MJ Research thermocycler (MJ Research, Watertown, MA) using the following conditions:

**Denaturing:**
95°C, 2 minutes, 0 seconds

**Annealing:**
For 10 cycles
94°C, 0 minute, 30 seconds
66°C, 1 minute, 0 second
72°C, 2 minutes, 30 seconds

**Extension:**
For 20 cycles
94°C, 0 minute, 30 seconds
61°C, 1 minute, 0 second
72°C, 2 minutes, 30 seconds

**Final extension:**
68°C, 1 minute, 0 second

The PCR product was run on a 1.1% agarose gel, transferred to nylon membrane and hybridized using the 700 bp PCR product obtained from amplification of the positive control.

**Schedule of evaluations.** The following evaluations and tests were performed as part of pre-treatment screening; written protocol-specific informed consent, medical history, assessment of performance status, and physical examination; also included were: electrocardiogram, chest X-ray, pulmonary function tests, stress echocardiogram, consultation, and evaluation by cardiologist.

Blood samples were taken for: hematology (complete blood count with differential platelet count), chemistries (blood urea nitrogen, Cr, Na<sup>+</sup>, K<sup>+</sup>, CO<sub>2</sub>, Cl<sup>-</sup>, Mg<sup>++</sup>, Ca<sup>++</sup>, phosphorus, albumin, alkaline phosphatase, alanine transaminase, aspartate transaminase, total bilirubin, total protein, glucose), prothrombin time/partial thromboplastin time, d-dimer, lactate dehydrogenase, tumor-specific markers (if applicable), and serum pregnancy test in women of childbearing potential; urine analysis; assessment of tumor size by physical measurement or with radiographic imaging, e.g., magnetic resonance imaging, computed tomography scan. Tumor imaging was required within 28 days before study drug infusion.

The following evaluations were performed at visits 2, 4, 6, and 8 (study weeks 1, 2, 3, and 4): symptom-oriented physical examination was done once weekly and symptom-oriented examination was done as needed at intervening study visits; assessment of performance status; review of medical history including concomitant medications and adverse events; on visits 2 and 6 only, before infusion, blood samples (5 ml) were taken for pharmacokinetics analysis of SGT-53.

**ACKNOWLEDGMENTS**
These studies were supported by SynerGene Therapeutics, Inc. and a research grant from SynerGene Therapeutics, Inc. (to K.F.P.). The authors thank Leanne Sleer for her contributions to this study. We also thank Susan W. Mill for manuscript preparation. E.H.C. is an inventor of the described technology for which several patents owned by Georgetown University have been issued. The patents have been licensed to SynerGene Therapeutics Inc. for commercial development. E.H.C. owns equity interests in SynerGene. In addition, E.H.C. serves as a non-paid scientific consultant to SynerGene. The other authors declared no conflict of interest.
REFERENCES


